Abstract 3581
Background
Ageing is a global phenomenon and has huge impact in healthcare. Still emerging in developing nations, there has been no major national innitiative focusing on oncologic geriatric patients (pts). The study describes a program to > 70y cancer pts in A C Camargo Cancer Center. We hypothesized that incorporating CGA into daily practice can improve individualized care.
Methods
Previous aims were to evaluate if: 1) CGA could be feasible in daily practice; 2) it could be useful as a tool in treatment/tx decision making; 3) analyse the impact of CGA in the selection of tx, with its ability to predict complications (such as dosis reduction, hospitalization, or tx discontinuation) in an Oncogeriatric Unit. The present study is to present the long term survival of those pts, candidates to receive systemic tx, who underwent CGA assessments, which included scales of: ADL (Katz, Lawton), mini-nutritional assessment, depression (GDS), comorbidities and polypharmacy. Patients were classified as fit, borderline or frail. Fit pts received mainly full treatment; frail/borderline pts, mainly modified tx or specific supportive care.
Results
From Oct 25/10-Dec/12/12, 638 pts were included to be prospectively evaluated - female 55%; cancers (%): breast 26, prostate 12, colorectal 12, hematologic 8. Katz A = 68%, Lawton 27=45%; polipharmacy ( > =5): 48%; depression 29%, undernutrition: 21%. We have previously presented (ASCO 2014) that there was an association between the choice of oncologic treatment (original vs modified or with additional dose reduction) with Katz, Lawton, depression and nutrition scales (p < =0.035); as well as the ability to complete the individualized proposed treatment, which was correlated with Lawton (p = 0.04) scale. Hospitalization during chemotherapy was associated with comorbidities, altered Katz, Lawton and depression scales (p < =0.038). With 610 pts evaluable, median survival was 51.7 months.
Conclusions
We could find a high long term survival of 70+ cancer pts, showing CGA to be feasible and allowing long term survival follow-up. However, many pts have been lost to follow-up. How to better perform in pts' adherence and to reduce bias must be a concern in real world geriatric oncology.
Clinical trial identification
Legal entity responsible for the study
Aldo L.A. Dettino; Grupo de Assistencia, Ensino e Pesquisa em Oncologia (GAEPO).
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.
Presenter: Guek Eng Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers
Presenter: Agnese Losurdo
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4755 - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer
Presenter: Chihwan Cha
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2741 - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
Presenter: Anees Hassan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3356 - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Presenter: Da Young Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4020 - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
Presenter: Yan Xu
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers
Presenter: Elodie Klajer
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4516 - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy
Presenter: Nawale Hajjaji
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract